Chronic lymphocytic leukaemia—what is new and notable in 2021, with a special focus on COVID-19

In the last few years, treatment of patients exhibiting chronic lymphocytic leukaemia has changed extensively due to advances in the development of targeted therapies. The role of immunochemotherapy has been for the most part replace and the guidelines have been modified accordingly. Herein, we give...

Descripción completa

Detalles Bibliográficos
Autores principales: Prochazka, Katharina T., Neumeister, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Vienna 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8356209/
https://www.ncbi.nlm.nih.gov/pubmed/34394761
http://dx.doi.org/10.1007/s12254-021-00735-z
_version_ 1783736900624842752
author Prochazka, Katharina T.
Neumeister, Peter
author_facet Prochazka, Katharina T.
Neumeister, Peter
author_sort Prochazka, Katharina T.
collection PubMed
description In the last few years, treatment of patients exhibiting chronic lymphocytic leukaemia has changed extensively due to advances in the development of targeted therapies. The role of immunochemotherapy has been for the most part replace and the guidelines have been modified accordingly. Herein, we give an overview on updated onkopedia guidelines, studded with updates of the landmark studies of the latest American Society of Hematology (ASH) meeting. In addition, since still crucial, recommendations concerning coronavirus disease 2019 (COVID-19) in chronic lymphocytic leukaemia patients will be covered.
format Online
Article
Text
id pubmed-8356209
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer Vienna
record_format MEDLINE/PubMed
spelling pubmed-83562092021-08-11 Chronic lymphocytic leukaemia—what is new and notable in 2021, with a special focus on COVID-19 Prochazka, Katharina T. Neumeister, Peter Memo Review In the last few years, treatment of patients exhibiting chronic lymphocytic leukaemia has changed extensively due to advances in the development of targeted therapies. The role of immunochemotherapy has been for the most part replace and the guidelines have been modified accordingly. Herein, we give an overview on updated onkopedia guidelines, studded with updates of the landmark studies of the latest American Society of Hematology (ASH) meeting. In addition, since still crucial, recommendations concerning coronavirus disease 2019 (COVID-19) in chronic lymphocytic leukaemia patients will be covered. Springer Vienna 2021-08-11 2021 /pmc/articles/PMC8356209/ /pubmed/34394761 http://dx.doi.org/10.1007/s12254-021-00735-z Text en © Springer-Verlag GmbH Austria, part of Springer Nature 2021 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Review
Prochazka, Katharina T.
Neumeister, Peter
Chronic lymphocytic leukaemia—what is new and notable in 2021, with a special focus on COVID-19
title Chronic lymphocytic leukaemia—what is new and notable in 2021, with a special focus on COVID-19
title_full Chronic lymphocytic leukaemia—what is new and notable in 2021, with a special focus on COVID-19
title_fullStr Chronic lymphocytic leukaemia—what is new and notable in 2021, with a special focus on COVID-19
title_full_unstemmed Chronic lymphocytic leukaemia—what is new and notable in 2021, with a special focus on COVID-19
title_short Chronic lymphocytic leukaemia—what is new and notable in 2021, with a special focus on COVID-19
title_sort chronic lymphocytic leukaemia—what is new and notable in 2021, with a special focus on covid-19
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8356209/
https://www.ncbi.nlm.nih.gov/pubmed/34394761
http://dx.doi.org/10.1007/s12254-021-00735-z
work_keys_str_mv AT prochazkakatharinat chroniclymphocyticleukaemiawhatisnewandnotablein2021withaspecialfocusoncovid19
AT neumeisterpeter chroniclymphocyticleukaemiawhatisnewandnotablein2021withaspecialfocusoncovid19

Ejemplares similares